Advertisement
Frequency Therapeutics In... (FREQ)
Company Description
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function.
Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.
The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss.
It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone.
The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.
Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Country | United States |
IPO Date | Oct 3, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 46 |
CEO | David L. Lucchino |
Advertisement
Contact Details
Address: 75 Hayden Avenue Lexington, Massachusetts United States | |
Website | https://www.frequencytx.com |
Stock Details
Ticker Symbol | FREQ |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001703647 |
CUSIP Number | 35803L108 |
ISIN Number | US5009461089 |
Employer ID | 47-2324450 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Wendy S. Arnold | Chief People Officer |
Dr. Carl P. LeBel Ph.D. | Chief Devel. Officer |
Dr. Dana C. Hilt M.D. | Chief Medical Officer (acting) |
Dr. John L. LaMattina Ph.D. | Senior Advisor & Member of PCA Regenerative Medicine Advisory Board |
Dr. Lisa Geller J.D., Ph.D. | Senior Vice President of Intellectual Property |
Dr. Quentin McCubbin Ph.D. | Chief Manufacturing Officer |
Dr. William W. Chin M.D. | Senior Vice President of Translational Medicine |
James P. Abely | Associate General Counsel & Secretary |
Jason Glashow | Senior Vice President of Corporation Affairs |
Richard J. Mitrano | Vice President of Finance & Operations |
Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | 4 | Filing |
Apr 01, 2025 | 4 | Filing |
Apr 01, 2025 | 3 | Filing |
Mar 27, 2025 | 8-K | Current Report |
Mar 18, 2025 | S-8 | Filing |
Mar 18, 2025 | 10-K | Annual Report |
Mar 18, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 11, 2025 | 3 | Filing |